Plasma somatostatin levels in patients with chronic idiopathic intestinal pseudo-obstruction

Am J Gastroenterol. 1997 Oct;92(10):1884-6.

Abstract

Objectives: Somatostatin participates in the control of gut motility. Recently, somatostatin analogs have been proposed as therapeutic agents for chronic intestinal pseudo-obstruction, although the endogenous somatostatin pattern has never been assessed in this syndrome. We aimed to evaluate fasting and postprandial plasma somatostatin levels in patients with chronic idiopathic intestinal pseudo-obstruction (CIIP).

Methods: We studied eight patients with CIIP and 10 healthy volunteers. Blood samples were taken at regular intervals while patients and subjects fasted and during the 3 h after a standard solid/liquid meal (550 kcal) had been eaten. Somatostatin was measured by radioimmunoassay.

Results: Fasting somatostatin levels were normal, whereas postprandial peptide responses were markedly impaired or even absent in patients with CIIP.

Conclusions: An impaired postprandial somatostatin response in patients with CIIP seems to be characteristic of this heterogenous disorder. Whether the lack of somatostatin response to a meal identifies patients with severe gut dysmotility for whom treatment with somatostatin analogs would be useful remains to be verified.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / analysis
  • Chronic Disease
  • Fasting
  • Female
  • Humans
  • Intestinal Pseudo-Obstruction / blood*
  • Male
  • Middle Aged
  • Pancreatic Polypeptide / blood
  • Postprandial Period
  • Somatostatin / blood*

Substances

  • Blood Glucose
  • Somatostatin
  • Pancreatic Polypeptide